Is there a best timing for benign prostatic hyperplasia surgery?

5 alpha-reductase inhibitors Alpha-blocker Benign prostatic hyperplasia Green light Holep Laser Lower urinary tract symptoms Transurethral resection of the prostate

Journal

The French journal of urology
ISSN: 2950-3930
Titre abrégé: Fr J Urol
Pays: France
ID NLM: 9918752079106676

Informations de publication

Date de publication:
Mar 2024
Historique:
received: 17 03 2023
revised: 12 06 2023
accepted: 26 10 2023
medline: 8 5 2024
pubmed: 8 5 2024
entrez: 8 5 2024
Statut: ppublish

Résumé

Treatment of lower urinary tract symptoms (LUTS) related to benign prostatic hyperplasia (BPH) has shifted over the last decades, with medical therapy becoming the primary treatment modality while surgery is being reserved mostly to patients who are not responding to medical treatment or presenting with complications from BPH. Here, we aim to to discuss the optimal timing of surgical management of LUTS/BPH. A literature search was conducted on Pub-Med/MEDLINE database to identify reports published from January 1990 until January 2022 by combining the following MeSH terms: "Lower Urinary Tract Symptoms"; "Prostatic Hyperplasia"; "Prostatic Hyperplasia/therapy"; "Prostatic Hyperplasia/complications"; "Treatment Outcome"; "Time-to-Treatment". Evidence supporting or not early surgical treatment of BPH was examined and reported in a pros and cons form. The "pro early surgery" highlighted the superior efficacy and cost-effectiveness of surgery over medical treatment for BPH, as well as the possibility of worse postoperative outcomes for delayed surgical treatment. The "con early surgery" considered that medical therapy is efficient in well-selected patients and can avoid the serious risks inherent to surgical treatment of BPH including important sexual side effects. Clinical trials comparing the outcomes for prolonged medical therapy versus early surgical treatment could determine which approach is more beneficial in the long-term in context of the aging population. Until then, both approaches have their advantages and patients should be involved in the treatment decision.

Identifiants

pubmed: 38717461
pii: S2950-3930(24)00008-1
doi: 10.1016/j.fjurol.2024.102574
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

102574

Informations de copyright

Copyright © 2024 Elsevier Masson SAS. All rights reserved.

Auteurs

Marc Fourmarier (M)

Department of Urology, CH Aix-Pertuis, Aix-en-Provence, France. Electronic address: marcfourmarier@hotmail.com.

Michael Baboudjian (M)

Department of Urology, North Hospital, Aix-Marseille University, AP-HM, Marseille, France.

Gregoire Robert (G)

Department of Urology, Bordeaux Pellegrin University Hospital, Bordeaux, France.

Souhil Lebdai (S)

Urology Department, University Hospital of Angers, 49933 Angers cedex 9, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH